<DOC>
	<DOCNO>NCT02019576</DOCNO>
	<brief_summary>Stereotactic radiotherapy ( SRT ) new type focus radiation therapy precisely accurately deliver high dose radiation tumour , spar much nearby normal organ . The use stereotactic radiotherapy result high rate tumour destruction minimal side effect well tolerate . Often stereotactic radiotherapy use try cure patient early stage cancer spread , less experience use patient cancer spread . The purpose study measure well stereotactic radiotherapy destroy kidney cancer tumour longer control Sunitinib measure much longer approach allow patient stay Sunitinib need switch another medication . Stereotactic radiotherapy use treat grow tumours patient continue Sunitinib .</brief_summary>
	<brief_title>Stereotactic Radiotherapy Metastatic Kidney Cancer Being Treated With Sunitinib</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>1 . Age ≥ 18 year . 2 . Able willing provide write informed consent comply study procedure . 3 . Karnofsky performance status ≥ 80 % . 4 . Favorable intermediate Heng prognostic group define two less follow factor : hemoglobin &lt; LLN ; serum correct calcium &gt; ULN ; Karnofsky performance status &lt; 80 % ; time initial diagnosis initiation therapy &lt; 1 year ; absolute neutrophil count &gt; ULN ; platelet count &gt; ULN . 5 . Histologic confirmation renal cell carcinoma clear cell component . 6 . Evidence measurable metastatic kidney cancer accord RECIST 1.1 criterion . 7 . Already receive firstline sunitinib therapy least 3 month least one imaging compare baseline show response change metastatic lesion ( Note : SD RECIST allow ≤ 19 % increase allow ) . 8 . Radiographic evidence ≤ 5 metastatic lesion progress . Of 5 progress lesion , maximum 3 lesion soft tissue . ( Ex . If bone metastases progress : maximum 3 soft tissue lesion . If bone metastases progress : maximum 5 total lesion 3 soft tissue . ) 9 . All progress metastasis amenable stereotactic radiotherapy . 10 . Each progression metastases fulfill one follow criterion oligoprogression : . Progression individual metastasis accord RECIST 1.1 criterion ( ≥ 20 % enlargement tumour vs. baseline nadir , take reference small diameter see prior start first line systemic therapy associate 5 mm minimum increase size ) ; b . Unambiguous development new metastatic lesion time scan take prior start firstline therapy sunitinib ; c. Progressive enlargement know metastasis 2 consecutive image study 23 month apart , receive firstline therapy sunitinib , minimum 5 mm increase size baseline . 1 . Evidence spinal cord compression . 2 . Inability safely treat site progress metastasis . 3 . Prior malignancy within past 5 year , exclude nonmelanoma skin cancer insitu cancer . 4 . Concurrent administration anticancer therapy apart firstline sunitinib . 5 . Diagnosis ataxia telangiectasia active collagen vascular disease . 6 . Other condition , illness , psychiatric condition laboratory abnormality may increase risk associate study participation stereotactic radiotherapy administration , may interfere interpretation study result judgment investigator would make patient inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Metastatic renal cell carcinoma</keyword>
	<keyword>mRCC</keyword>
	<keyword>Clear cell</keyword>
</DOC>